Senores Pharmaceuticals IPO Details, Financials, Valuation & Peers
Explore Senores Pharmaceuticals IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company specializing in the development and manufacturing of a wide range of pharmaceutical products for Regulated Markets such as the US, Canada, and the UK, as well as Emerging Markets across 43 countries. With a focus on specialty, underpenetrated, and complex pharmaceutical products, the company leverages advanced R&D capabilities to deliver differentiated solutions across various therapeutic areas and dosage forms. Its robust pipeline includes Competitive Generic Therapeutic (CGT) designated products and ANDA approvals, establishing it as a preferred partner for key pharmaceutical companies globally. Senores also engages in Contract Development and Manufacturing Operations (CDMO) and Contract Manufacturing Operations (CMO), providing end-to-end services from drug development to regulatory compliance.
Key Points:
- Global Presence:
- Predominantly serves regulated markets in the US, Canada, and the UK.
- Presence in 43 emerging markets, expanding reach to semi-regulated markets.
- Research and Development Strength:
- Focuses on developing complex, specialty pharmaceutical products.
- Pipeline includes 33 ANDAs under development and several approved products with Competitive Generic Therapeutic (CGT) designations.
- Regulated Markets Portfolio:
- Marketed Products: Includes ANDAs and sourced products catering to niche markets.
- CDMO/CMO Services: Offers bioavailability studies, regulatory support, and manufacturing services to clients like Alkem Laboratories and Jubilant Cadista.
- Key Partnerships:
- Collaborates with global and Indian pharmaceutical giants such as Prasco LLC, Sun Pharmaceuticals, Dr. Reddy’s Laboratories, and Cipla USA.
- Manufacturing Excellence:
- Operates a US FDA-approved oral solid dosage facility in Atlanta, enabling efficient production and CDMO services.
- Capability to manufacture critical care injectables and controlled substances for US government contracts.
- Commercial Success:
- Significant market share for key products like Acetaminophen Butalbital, Chlorzoxazone, and Mexiletine Hydrochloride.
- Enjoyed six-month exclusivity for specific CGT-designated products in the US.
- Emerging Market Growth:
- Actively expanding into regions like South Africa, UAE, Israel, and Saudi Arabia through CDMO/CMO contracts and innovative product offerings.
Objects of the Issue
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
- Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- Investment in the Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary;
- Funding the working capital requirements of the Company
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements;
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 20 Dec - 24 Dec 2024 |
| IPO Price Band | ₹372 - ₹391 per share |
| Fresh Issue | ₹500 crore |
| Offer For Sale | ₹82.11 crore |
| Total IPO Size | ₹582.11 crore |
| Face Value | ₹10 |
| Listing On | BSE, NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 20 Dec 2024 |
| IPO Closing Date | 24 Dec 2024 |
| Basis Of Allotment | 26 Dec 2024 |
| Refunds | 27 Dec 2024 |
| Demat Transfer | 27 Dec 2024 |
| IPO Listing Date | 30 Dec 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | Sep 2024 |
|---|---|---|---|---|
| Total Income | 14.63 | 39.02 | 217.34 | 183.35 |
| Total Expenses | 13.49 | 26.58 | 192.40 | 153.95 |
| Net Profit/Loss | 0.99 | 8.43 | 32.71 | 23.94 |
| NPM (*) | 7.00 | 23.87 | 15.25 | 13.23 |
| Total Assets | 59.15 | 131.05 | 621.88 | 678.08 |
| Total Liabilities | 22.56 | 85.55 | 390.17 | 359.02 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | Sep 2024 |
|---|---|---|---|---|
| EPS | 1.81 | 6.65 | 12.21 | 7.20 |
| ROE (%) | 4.35 | 20.55 | 23.60 | 8.69 |
| ROCE (%) | 5.38 | 18.56 | 11.73 | 7.59 |
| D/E Ratio | 0.39 | 1.34 | 1.07 | 0.76 |
| Current Ratio | 2.74 | 0.99 | 1.01 | 1.69 |
| EBITDA MARGIN (%) | 17.03 | 46.28 | 20.70 | 25.91 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Revenue | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| Senores Pharmaceuticals Limited | 214.52 | 32.02 | 12.21 | 23.60 | 66.96 |
| Ajanta Pharma Limited | 4,208.71 | 43.34 | 64.77 | 23.47 | 281.60 |
| Alembic Pharmaceuticals Limited | 6,228.63 | 33.90 | 31.33 | 13.40 | 245.12 |
| Caplin Point Laboratories Limited | 1,694.10 | 40.84 | 59.90 | 21.69 | 309.03 |
| Gland Pharma Limited | 5,664.72 | 37.27 | 46.90 | 9.26 | 529.65 |
| Strides Pharma Science Limited | 4,051.12 | Negative | -7.76 | -4.44 | 225.43 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
IPO Reservation
| Investor Type | Shares Offered |
|---|---|
| Qualified Institutional Buyer (QIB) | Not less than 75% |
| Non-Institutional Investor (NII/HNI) | Not less than 15% |
| Retail Individual Investor (RII) | Not less than 10% |
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 97.84 |
| Non-Institutional Investor (NII/HNI) | 100.35 |
| Retail Individual Investor (RII) | 93.16 |
| Total | 97.86 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited)
Phone: + 91 810 811 4949
Email: ipo.helpdesk@linkintime.co.in
Website: https://linkintime.co.in/
Company Promoters
- SWAPNIL JATINBHAI SHAH
- ASHOKKUMAR VIJAYSINH BAROT
Lead Managers
- Equirus Capital Private Limited
- Ambit Private Limited
- Nuvama Wealth Management Limited
Company Address
Senores Pharmaceuticals Limited
1101 to 1103, 11th floor, South Tower, ONE 42 opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: www.senorespharma.com
FAQs
- What is the issue size of the Senores Pharmaceuticals IPO?The Senores Pharmaceuticals IPO has an issue size of ₹582.11 crore. This includes a fresh issue of ₹500 crore and an offer for sale (OFS) of ₹82.11 crore.
- What is the price band of the Senores Pharmaceuticals IPO?The price band for the Senores Pharmaceuticals IPO is ₹372 - ₹391 per share.
- What are the bidding dates for the Senores Pharmaceuticals IPO?The Senores Pharmaceuticals IPO will open for bidding on 20 Dec 2024 and close on 24 Dec 2024.
- What is the allotment date for the Senores Pharmaceuticals IPO?The allotment date for the Senores Pharmaceuticals IPO is 26 Dec 2024.
- What is the minimum lot size and investment required for the Senores Pharmaceuticals IPO?The minimum lot size for the Senores Pharmaceuticals IPO is 38 shares and the minimum investment required is ₹14,858.
- What is the listing date for the Senores Pharmaceuticals IPO?The listing date for the Senores Pharmaceuticals IPO is 30 Dec 2024.
- What is the Senores Pharmaceuticals IPO grey market premium?The grey market premium (GMP) for the Senores Pharmaceuticals IPO is currently at ₹284, with an expected listing gain of approximately 72.63%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.